argenx NV ADR (ARGX)vsInvivyd Inc. (IVVD)
ARGX
argenx NV ADR
$891.32
+5.82%
HEALTHCARE · Cap: $55.09B
IVVD
Invivyd Inc.
$1.03
-7.21%
HEALTHCARE · Cap: $303.45M
Smart Verdict
WallStSmart Research — data-driven comparison
argenx NV ADR generates 8389% more annual revenue ($4.74B vs $55.87M). ARGX leads profitability with a 31.4% profit margin vs -138.9%. ARGX earns a higher WallStSmart Score of 73/100 (B).
ARGX
Strong Buy73
out of 100
Grade: B
IVVD
Hold36
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+62.4%
Fair Value
$2217.64
Current Price
$891.32
$1326.32 discount
Intrinsic value data unavailable for IVVD.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Keeps 31 of every $100 in revenue as profit
Strong operational efficiency at 30.0%
Revenue surging 62.6% year-over-year
Earnings expanding 114.0% YoY
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Reasonable price relative to book value
Conservative balance sheet, low leverage
Revenue surging 21.6% year-over-year
Areas to Watch
Premium valuation, high expectations priced in
Weak financial health signals
Trading at 188.4x book value
0.0% earnings growth
Smaller company, higher risk/reward
Weak financial health signals
ROE of -38.2% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : ARGX
The strongest argument for ARGX centers on Profit Margin, Operating Margin, Revenue Growth. Profitability is solid with margins at 31.4% and operating margin at 30.0%. Revenue growth of 62.6% demonstrates continued momentum.
Bull Case : IVVD
The strongest argument for IVVD centers on Price/Book, Debt/Equity, Revenue Growth. Revenue growth of 21.6% demonstrates continued momentum.
Bear Case : ARGX
The primary concerns for ARGX are P/E Ratio, Piotroski F-Score, Price/Book.
Bear Case : IVVD
The primary concerns for IVVD are EPS Growth, Market Cap, Piotroski F-Score.
Key Dynamics to Monitor
IVVD carries more volatility with a beta of 0.63 — expect wider price swings.
ARGX is growing revenue faster at 62.6% — sustainability is the question.
Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.
Bottom Line
ARGX scores higher overall (73/100 vs 36/100), backed by strong 31.4% margins and 62.6% revenue growth. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
argenx NV ADR
HEALTHCARE · BIOTECHNOLOGY · USA
argenx SE, a clinical-phase biotechnology company, focuses on the development of antibody-based therapies for the treatment of autoimmune diseases, hematology and cancer. The company is headquartered in Breda, the Netherlands.
Invivyd Inc.
HEALTHCARE · BIOTECHNOLOGY · USA
Adagio Therapeutics, Inc., a clinical-stage biopharmaceutical company, is focused on the discovery, development and commercialization of antibody-based solutions for infectious diseases in the United States. The company is headquartered in Waltham, Massachusetts.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?